Celgene Corporation (CELG)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
107.40+1.09 (+1.03%)
At close: 4:00 PM EDT
People also watch:
GILDBIIBREGNAMGNALXN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open106.51
Prev Close106.31
Bid106.03 x 300
Ask108.66 x 300
Day's Range105.69 - 107.50
52wk Range93.05 - 128.39
1y Target EstN/A
Market Cap83.25B
P/E Ratio (ttm)45.39
Beta1.47
Volume2,536,107
Avg Vol (3m)4,182,785
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Business Wire3 hours ago

    Oral OTEZLA® (apremilast) Long-Term Safety Data Presented at EADV Congress in Both Psoriasis and Psoriatic Arthritis

    Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation  , today announced that long-term safety findings from ongoing clinical trials of apremilast, the Company's oral, selective inhibitor of phosphodiesterase 4 , were presented at the European Academy of Dermatology and Venereology Annual Congress in Vienna, Austria.

  • Barrons.com18 hours ago

    Amgen: The Blame Game

    This morning, Amgen (AMGN) reported that its cancer drug Kyprolis failed to do what it hoped it would in a late-stage trial. RBC's Michael Yee and Judy Liu wonder if the design of the trial was to blame: Amgen announced the Clarion study (head to head versus Velcade) did not meet stat sig for progression free survival although survival did show a solid trend (Hr=1.21). This is a surprise since the prior Endeavor second line study was a very big success and today's result in first line may be due to lack of sufficient powering in our view, given strong trend in survival and deeper responses with Kyprolis should better especially earlier.

  • Celgene Corp. – Value Analysis (NASDAQ:CELG) : September 27, 2016
    Capital Cube18 hours ago

    Celgene Corp. – Value Analysis (NASDAQ:CELG) : September 27, 2016

    Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives Celgene Corp. a score of 69. Our analysis is based on comparing Celgene Corp. with the following peers – Amgen Inc., Gilead Sciences, Inc., Biogen Inc., OncoMed Pharmaceuticals, Inc., Eli Lilly and Company, Johnson & Johnson, Alexion Pharmaceuticals, Inc., Illumina, Inc., Epizyme, Inc. and ARIAD Pharmaceuticals, Inc. ... Read more (Read more...)